Search. Read. Cite.

Easy to search. Easy to read. Easy to cite with credible sources.

Molecular Endocrinology

Year: 2010  |  Volume: 24  |  Issue: 10  |  Page No.: 2019 - 2029

DHT Selectively Reverses Smad3-Mediated/TGF-{beta}-Induced Responses through Transcriptional Down-Regulation of Smad3 in Prostate Epithelial Cells

K Song, H Wang, T. L Krebs, B Wang, T. J Kelley and D. Danielpour

Abstract

Androgens suppress TGF-β responses in the prostate through mechanisms that are not fully explored. We have recently reported that 5-dihydrotestosterone (DHT) suppresses the ability of TGF-β to inhibit proliferation and induce apoptosis of prostatic epithelial cells and provided evidence that such suppression was fueled by transcriptional down-regulation of TGF-β receptor II (TβRII). We now show that androgen receptor (AR) activated by DHT suppresses the TGF-β-induced phosphorylation of Sma- and Mad-related protein (Smad)3 in LNCaP cells overexpressing TβRII under the control of a cytomegalovirus promoter, which is not regulated by DHT, suggesting that transcriptional repression of TβRII alone does not fully account for the impact of DHT on TGF-β responses. Instead, we demonstrate that such suppression occurs through loss of total Smad3, resulting from transcriptional suppression of Smad3. We provide evidence that DHT down-regulates the promoter activity of Smad3 in various prostate cancer cell lines, including NRP-154+AR, DU145+AR, LNCaP, and VCaP, at least partly through androgen-dependent inactivation of Sp1. Moreover, we show that overexpression of Smad3 reverses the ability of DHT to protect against TGF-β-induced apoptosis in NRP-154+AR, supporting our model that loss of Smad3 by DHT is involved in the protection against TGF-β-induced apoptosis. Together, these findings suggest that deregulated/enhanced expression and activation of AR in prostate carcinomas may intercept the tumor suppressor function of TGF-β through transcriptional suppression of Smad3, thereby providing new mechanistic insight into the development of castration-resistant prostate cancer.

View Fulltext